Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy
Lung · 2024
DOI: 10.1007/s00408-024-00742-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung, 2024. Verfasst von Julia F Söllner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany. julia.soellner@boehringer-ingelheim.com. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Lung Transplantation, Antifibrotic Agents, Disease Progression. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and e….
Abstract (Originalsprache)
PURPOSE: We investigated whether a 52-gene signature was associated with transplant-free survival and other clinically meaningful outcomes in patients with idiopathic pulmonary fibrosis (IPF) in the IPF-PRO Registry, which enrolled patients who were and were not taking antifibrotic therapy. METHODS: The 52-gene risk signature was implemented to classify patients as being at "high risk" or "low risk" of disease progression and mortality. Transplant-free survival and other outcomes were compared between patients with a low-risk versus high-risk signature. RESULTS: The 52-gene signature classified 159 patients as at low risk and 86 as at high risk; in these groups, respectively, 56.6% and 51.2% used antifibrotic therapy at enrollment. Among those taking antifibrotic therapy, patients with a low-risk versus high-risk signature were at decreased risk of death, a composite of lung transplant or death, and a composite of decline in DLco % predicted > 15%, lung transplant, or death. Similar results were observed in the overall cohort. CONCLUSIONS: These data suggest that the 52-gene signature can be used in patients with IPF treated with antifibrotic therapy to distinguish patients at higher risk of disease progression and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany. julia.soellner@boehringer-ingelheim.com.
- Staburo GmbH, Munich, Germany.
- Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany.
- Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
- Duke Clinical Research Institute, Durham, NC, USA.
- Duke University Medical Center, Durham, NC, USA.
ORCID-Profile: Megan L Neely, Thomas Schlange, Jamie L Todd, Margaret L Salisbury
Förderung
- The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and e…
Zitieren
APA
Söllner, J. F., Bentink, S., Hesslinger, C., Leonard, T. B., Neely, M. L., Patel, N. M., Schlange, T., Todd, J. L., Vinisko, R., Salisbury, M. L., & IPF-PRO Registry investigators (2024). Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy. Lung. https://doi.org/10.1007/s00408-024-00742-x
Vancouver
Söllner JF, Bentink S, Hesslinger C, Leonard TB, Neely ML, Patel NM, et al. Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy. Lung. 2024. doi:10.1007/s00408-024-00742-x
BibTeX
@article{Sllner2024,
author = {Söllner, Julia F and Bentink, Stefan and Hesslinger, Christian and Leonard, Thomas B and Neely, Megan L and Patel, Nina M and Schlange, Thomas and Todd, Jamie L and Vinisko, Richard and Salisbury, Margaret L and IPF-PRO Registry investigators, IPF-PRO Registry investigators},
title = {Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy},
journal = {Lung},
year = {2024},
doi = {10.1007/s00408-024-00742-x}
}
EUVIMED